ES2791251T3 - Péptidos de Ledgf y formulaciones de los mismos para el tratamiento de trastornos degenerativos - Google Patents

Péptidos de Ledgf y formulaciones de los mismos para el tratamiento de trastornos degenerativos Download PDF

Info

Publication number
ES2791251T3
ES2791251T3 ES13794410T ES13794410T ES2791251T3 ES 2791251 T3 ES2791251 T3 ES 2791251T3 ES 13794410 T ES13794410 T ES 13794410T ES 13794410 T ES13794410 T ES 13794410T ES 2791251 T3 ES2791251 T3 ES 2791251T3
Authority
ES
Spain
Prior art keywords
ledgf
peptide
composition
protein
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13794410T
Other languages
English (en)
Spanish (es)
Inventor
Uday Kompella
Rinku Baid
Arun Upadhyay
Sarath Yandrapu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado System
University of Colorado Colorado Springs
Original Assignee
University of Colorado System
University of Colorado Colorado Springs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/065620 external-priority patent/WO2013074988A1/en
Application filed by University of Colorado System, University of Colorado Colorado Springs filed Critical University of Colorado System
Application granted granted Critical
Publication of ES2791251T3 publication Critical patent/ES2791251T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
ES13794410T 2012-05-21 2013-05-21 Péptidos de Ledgf y formulaciones de los mismos para el tratamiento de trastornos degenerativos Active ES2791251T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261649847P 2012-05-21 2012-05-21
PCT/US2012/065620 WO2013074988A1 (en) 2011-11-17 2012-11-16 Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations
PCT/US2013/042074 WO2013177198A1 (en) 2012-05-21 2013-05-21 Ledgf peptides and formulations thereof for treatment of degenerative disorders

Publications (1)

Publication Number Publication Date
ES2791251T3 true ES2791251T3 (es) 2020-11-03

Family

ID=49624295

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13794410T Active ES2791251T3 (es) 2012-05-21 2013-05-21 Péptidos de Ledgf y formulaciones de los mismos para el tratamiento de trastornos degenerativos

Country Status (12)

Country Link
US (2) US9526760B2 (enExample)
EP (1) EP2852399B1 (enExample)
JP (2) JP6632376B2 (enExample)
CN (2) CN110054677A (enExample)
AU (1) AU2013266468B2 (enExample)
BR (1) BR112014028951A8 (enExample)
CA (1) CA2873771A1 (enExample)
DK (1) DK2852399T3 (enExample)
ES (1) ES2791251T3 (enExample)
IN (1) IN2014MN02461A (enExample)
RU (1) RU2617964C2 (enExample)
WO (1) WO2013177198A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013266468B2 (en) * 2012-05-21 2017-11-09 The Regents Of The University Of Colorado, A Body Corporate LEDGF peptides and formulations thereof for treatment of degenerative disorders
KR101748120B1 (ko) * 2015-07-13 2017-06-16 서울대학교산학협력단 나노입자-유리체 기반 단백질 복합체를 유효성분으로 포함하는 혈관신생억제용 조성물 및 이의 용도
US20180207293A1 (en) * 2017-01-25 2018-07-26 2C Tech Corp. Nanoparticles for sustained ophthalmic drug delivery and methods of use
US11793758B2 (en) 2018-06-22 2023-10-24 Bioralix B.V. Formulations of biological polymers for oral administration

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4221787A (en) 1978-03-28 1980-09-09 Interx Research Corporation Esteramide prodrugs of anti-inflammatory corticosteroids
US4469689A (en) 1983-03-30 1984-09-04 The Upjohn Company Sulfonate containing ester prodrugs of corticosteroids
US6750052B1 (en) 1997-07-23 2004-06-15 The Brigham And Women's Hospital, Inc. Lens epithelial cell derived growth factor
US7708915B2 (en) 2004-05-06 2010-05-04 Castor Trevor P Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
EP1562627A4 (en) 2002-08-23 2006-11-02 Mclean Hospital Corp CORTICOSTEROID CONJUGATES AND ITS USES
AU2003273633A1 (en) * 2002-09-26 2004-04-19 K.U.Leuven Research And Development Integrase cofactor
AU2003298786A1 (en) * 2002-11-26 2004-06-18 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
US20060166879A1 (en) 2002-12-20 2006-07-27 Chakshu Research Inc Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders
US20050181375A1 (en) * 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
JP2008512984A (ja) * 2004-05-28 2008-05-01 ダナ−ファーバー キャンサー インスティチュート，インコーポレイテッド 癌の同定、評価、予防および治療のための組成物、キットおよび方法
EP1971288B1 (en) 2005-12-30 2013-02-13 Neurotech USA, Inc. Micronized device for the delivery of biologically active molecules and methods of use thereof
CA2660286A1 (en) * 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
WO2008053478A2 (en) 2006-10-30 2008-05-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions and methods for inhibiting hiv-1 replication and integrase activity
US8168393B2 (en) * 2007-02-16 2012-05-01 The Brigham And Women's Hospital, Inc. Compositions and methods for diagnosing tumors using LEDGF/p75
JP5616336B2 (ja) * 2008-06-26 2014-10-29 オルファザイム エーピーエスＯｒｐｈａｚｙｍｅ Ａｐｓ 酵素活性の調節因子としてのＨｓｐ７０の使用
GB0812742D0 (en) * 2008-07-11 2008-08-20 Critical Pharmaceuticals Ltd Process
US10234453B2 (en) * 2011-07-01 2019-03-19 Inova Diagnostics, Inc. Method for increasing specificity of diagnostic tests for autoimmune diseases
AU2013266468B2 (en) * 2012-05-21 2017-11-09 The Regents Of The University Of Colorado, A Body Corporate LEDGF peptides and formulations thereof for treatment of degenerative disorders

Also Published As

Publication number Publication date
CN104470534A (zh) 2015-03-25
WO2013177198A1 (en) 2013-11-28
IN2014MN02461A (enExample) 2015-07-10
US9526760B2 (en) 2016-12-27
EP2852399B1 (en) 2020-02-19
JP2018172386A (ja) 2018-11-08
EP2852399A1 (en) 2015-04-01
AU2013266468B2 (en) 2017-11-09
DK2852399T3 (da) 2020-05-04
US20170129929A1 (en) 2017-05-11
JP2015519343A (ja) 2015-07-09
AU2013266468A1 (en) 2014-12-18
BR112014028951A8 (pt) 2021-09-14
US10221226B2 (en) 2019-03-05
CA2873771A1 (en) 2013-11-28
RU2617964C2 (ru) 2017-04-28
US20150147404A1 (en) 2015-05-28
CN110054677A (zh) 2019-07-26
RU2014151603A (ru) 2016-07-10
JP6632376B2 (ja) 2020-01-22
BR112014028951A2 (pt) 2017-07-25
EP2852399A4 (en) 2016-03-23

Similar Documents

Publication Publication Date Title
Liu et al. Penetratin, a potentially powerful absorption enhancer for noninvasive intraocular drug delivery
ES2644016T3 (es) Péptidos para su uso en el tratamiento tópico de enfermedades neurodegenerativas retinianas, en particular en estadios tempranos de retinopatía diabética y otras enfermedades retinianas en las que la neurodegeneración desempeña un papel esencial
US20120315256A1 (en) Use of transforming growth factor - beta 1 (tgf-b1) inhibitor peptides for the treatment of corneal fibrosis and/or haze
EP3452075B1 (en) Ophthalmic pharmaceutical composition
EP3065765B1 (en) Use of il-22 dimers in manufacture of medicaments for treating pancreatitis
JP6884755B2 (ja) ペプチド組成物および使用方法
US10221226B2 (en) LEDGF peptides and formulations thereof for treatment of degenerative disorders
WO2013016578A2 (en) Controlled release of ocular biopharmaceuticals using bioresponsive protein polymers
CN114073774A (zh) 药物和野生型穿膜肽衍生物的组合物
CN116570706A (zh) 使用多肽治疗白内障的方法
WO2017095769A1 (en) Histatins and methods of use thereof
US11207423B2 (en) Nanocarriers having surface conjugated peptides and uses thereof for sustained local release of drugs
WO2013005603A9 (ja) 結膜におけるアレルギー性炎症の予防及び／又は治療剤
AU2020419590A1 (en) Stable formulations of silk-derived protein
CN118206667A (zh) 一种脂质化修饰抗血管生成多肽、纳米胶束、温敏性水凝胶及制备方法和应用
WO2017121766A1 (en) Pharmaceutical formulations and their use for the treatment of retinitis pigmentosa
Asensio A novel nanoparticle-based system for sustained intravitreal drug delivery
EP4475866A1 (en) Peptides and methods of use thereof in treating ocular disorders
Mackay et al. Treatment of the Cornea Using Transcytotic Delivery into the Tear Film
Baid Lens epithelium derived growth factor (1-326): a new protein drug for retinal diseases
WO2020016474A1 (es) Nanosistemas con complejos